News

Stromal cells in the laboratory.

Mesenchymal Stromal Cells Shown to Prevent Lung and Skin Fibrosis, Restore Wound Healing

A cross-disciplinary group of researchers at the University of Miami Miller School of Medicine has found that allogeneic adipose-derived mesenchymal stromal cells (ASCs) will prevent lung and skin fibrosis, and restore wound healing.

Read more on the Miller School website »

51st Miami Winter Symposium Opens January 28

Stem Cells: Today’s Research Tomorrow’s Therapies will be the focus of the 51st Miami Winter Symposium, which will take place January 28-31 at the downtown Hyatt Regency Hotel January 28-31.

Read more on the Miller School website »

Six-minute walk test results improved with stem cell therapy.

Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty

Buoyed by promising results of a Phase I study demonstrating the safety of mesenchymal stem cell therapy to treat frailty in older adults, researchers at the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have taken it a step further. Now Phase II randomized, placebo-controlled trial findings have verified their initial study.

Read more on the Miller School website »

Joshua M. Hare, M.D.

Study Shows Stem Cell Therapy Dosing Matters in Ischemic Cardiomyopathy

The Phase II TRIDENT study, led by Joshua M. Hare, M.D., and colleagues at the University of Miami Miller School of Medicine, found that a dose of 100 million allogeneic human mesenchymal stem cells, versus 20 million, was more effective in decreasing scar tissue and restoring left ventricular ejection fraction in study of 30 people with ischemic cardiomyopathy.

Read more on the Miller School website »

The science of gene editing has been advancing more rapidly than have ethical guidelines for its use, say experts.

New Ethics Guidelines for Gene Editing

On August 3, The American Journal of Human Genetics published the American Society for Human Genetics’ policy statement on germline gene editing in humans. Representing the Miller School on the task force was Rosario Isasi, J.D., M.P.H., a bioethicist and lawyer whose work focuses on the regulation of human genetic technologies. We asked Isasi to discuss the policy statement and its broad implications.

Read more on the Miller School website »

News Archives »